Alyssa Sanchez
Family · Mission, TXNPI 1417450438
Payments from drug & device makers
Across 279 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AstraZeneca$633
- Amgen$523
- Abbott$457
- GSK$207
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,58597%
- Education$1473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 94 | $1,364 |
| Lilly USA, LLC | 58 | $1,080 |
| AstraZeneca | 24 | $633 |
| Amgen | 21 | $523 |
| Abbott | 11 | $457 |
| GSK | 10 | $207 |
| Astellas Pharma US Inc | 6 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $140 |
| AbbVie | 7 | $137 |
| Dexcom, Inc. | 1 | $124 |
| UCB, Inc. | 1 | $104 |
| Avanir Pharmaceuticals, Inc. | 1 | $98 |
| Exact Sciences | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Johnson & Johnson | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 2 | $55 |
| Novartis | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Paratek Pharmaceuticals, Inc. | 3 | $41 |
| Amarin Pharma, Inc. | 2 | $35 |
| Bayer | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $18 |
| Vivus LLC | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Pfizer | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$240
- ENSITE PRECISION$158
- EVENITY$142
- Prolia$142
- FREESTYLE LIBRE 3$127
- AIRSUPRA$125
- DEXCOM G6 TRANSMITTER$124
- MOUNJARO$115
- FARXIGA$115
- RYBELSUS$102
How this compares
$5,732 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $183,527 |
| JardianceEmpagliflozin | 90 | $105,675 |
| FarxigaDapagliflozin Propanediol | 99 | $96,773 |
| MounjaroTirzepatide | 67 | $73,210 |
| RybelsusSemaglutide | 29 | $68,830 |
| ProliaDenosumab | 41 | $67,911 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $44,994 |
| JanuviaSitagliptin Phosphate | 35 | $43,244 |
| TrulicityDulaglutide | 18 | $31,144 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $27,667 |
| MyrbetriqMirabegron | 31 | $24,188 |
| EntrestoSacubitril/Valsartan | 17 | $17,921 |
| SynjardyEmpagliflozin/Metformin Hcl | 18 | $16,737 |
| EliquisApixaban | 11 | $16,534 |
| VascepaIcosapent Ethyl | 30 | $15,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,364 | $252,357172 claims |
| Boehringer IngelheimJardiance, Synjardy | $18 | $122,413108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,080 | $104,35585 claims |
| AstraZenecaFarxiga | $633 | $96,77399 claims |
| AmgenProlia | $523 | $67,91141 claims |
| GSKTrelegy Ellipta | $207 | $27,66732 claims |
| Astellas Pharma US IncMyrbetriq | $175 | $24,18831 claims |
| NovartisEntresto | $48 | $17,92117 claims |
| PfizerEliquis | $16 | $16,53411 claims |
| AbbVieLinzess | $137 | $12,50919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Mission
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.